Drugs / TKM-100802
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02041715 | Jan 2014 → Jul 2015 | Ebola hemorrhagic fever | Arbutus Biopharma Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TKM-100802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02041715 ↗ |
| Route | Intravenous | “IV infusion” NCT02041715 ↗ |